Qiagen (NYSE: QGEN; Frankfurt Prime Standard: QIA), headquartered in Venlo, Netherlands, and Nvidia have announced a collaboration integrating Nvidia’s accelerated computing infrastructure and BioNeMo platform with Qiagen Digital Insights’ curated biomedical knowledge bases to support AI drug discovery workflows across target identification, biomarker discovery, and hypothesis generation. The agreement was disclosed at the 2026 BIO-IT World Conference & Expo in Boston, with initial access to be offered through pilot programs for select pharmaceutical and biotechnology partners before broader availability.
The collaboration pairs two distinct technology layers. Qiagen Digital Insights contributes the Qiagen Discovery Platform, a biomedical knowledge graph built over 25 years of curation spanning genes, diseases, pathways, compounds, clinical insights, and more than 30,000 disease entities. Nvidia contributes accelerated computing infrastructure and the Nvidia BioNeMo platform, which provides the generative AI model-building and deployment layer, along with frameworks including PyTorch Geometric and GPU-accelerated GraphRAG systems.
The integrated system applies graph-based AI retrieval and reasoning techniques over Qiagen’s biomedical knowledge graph, enabling researchers to query interconnected biological data using natural language while retaining links to structured scientific evidence. The stated application areas include therapeutic target discovery and validation, drug repurposing, biomarker identification, pathway analysis, and hypothesis generation from multi-omics data.
Graph-based AI and the drug discovery platform architecture
The technical architecture is centered on GraphRAG, a retrieval-augmented generation approach applied to graph-structured biomedical data. Rather than querying flat databases, the system traverses relationships across biological entities — connecting genes to diseases, compounds to pathways, and clinical evidence to molecular mechanisms — to surface contextually grounded insights. Nvidia’s GPU-accelerated computing layer enables this traversal at scale, while BioNeMo provides the interface through which researchers interact with the knowledge graph using natural language queries.
Qiagen’s approach addresses a known bottleneck in computational drug discovery: the gap between raw data volume and interpretable, evidence-linked outputs. By anchoring AI-generated hypotheses to curated scientific literature and structured knowledge, the system is intended to give research teams a basis for assessing whether a given insight is biologically credible before committing resources to experimental follow-up.
Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at Qiagen, said the collaboration would allow the company to “accelerate the impact” of its curated knowledge base by combining it with advanced AI to support target identification, biomarker research, and hypothesis generation.